The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients

Author： van Schaik Ron HN   Kok Marleen   Sweep Fred CGJ   van Vliet Martin   van Fessem Marianne   Meijer-van Gelder Marion E   Seynaeve Caroline   Lindemans Jan   Wesseling Jelle   Van ‘t Veer Laura J   Span Paul N   van Laarhoven Hanneke   Sleijfer Stefan   Foekens John A   Linn Sabine C   Berns Els MJJ  

Publisher： Future Medicine

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.12, Iss.8, 2011-08, pp. : 1137-1146

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen

By Ruiter Rikje   Bijl Monique J   van Schaik Ron HN   Berns Els MJJ   Hofman Albert   Coebergh Jan-Willem W   van Noord Charlotte   Visser Loes E   Stricker Bruno HCh  

Pharmacogenomics, Vol. 11, Iss. 10, 2010-10 ,pp. : 1367-1375

Future Medicine

Access to resources Recommend Favorite

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients

By Margolin Sara   Lindh Jonatan D   Thorén Linda   Xie Hanjing   Koukel Larissa   Dahl Marja-Liisa   Eliasson Erik  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 613-622

Future Medicine

Access to resources Recommend Favorite

Letrozole superior to tamoxifen in advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1324, 2002-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

A Stochastic Economic Evaluation of Letrozole versus Tamoxifen as a First-Line Hormonal Therapy: For Advanced Breast Cancer in Postmenopausal Patients

By Karnon J.  

PharmacoEconomics, Vol. 21, Iss. 7, 2003-01 ,pp. : 513-525

Adis International

Access to resources Recommend Favorite

Docetaxel as Single-Agent Treatment in Elderly Patients with Advanced Breast Cancer

By Lorenzo I.   Constenla M.   Palacios P.   García-Arroyo F.R.   Fernández I.   Campos B.   Salgado L.   Carrete N.  

Clinical Drug Investigation, Vol. 25, Iss. 4, 2005-01 ,pp. : 249-256

Adis International

Access to resources Recommend Favorite